Comparisons between patients with trimethoprim–sulfamethoxazole-susceptible and trimethoprim–sulfamethoxazole-resistant Stenotrophomonas maltophilia monomicrobial bacteremia: A 10-year retrospective study

Journal of Microbiology, Immunology and Infection

Volumn 49, Issue 3, 2016, Pages 378-386

  Wang, Ching Hsun ^a   Lin, Jung Chung ^a   Lin, Hsin An ^a   Chang, Feng Yee ^a   Wang, Ning Chi ^a   Chiu, Sheng Kang ^a   Lin, Te Yu ^a   Yang, Ya Sung ^a   Kan, Li Ping ^a   Yang, Chin Hsuan ^a   Chan, Ming Chin ^a   Yeh, Kuo Ming ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

bacteremia; resistance; Stenotrophomonas maltophilia; trimethoprim sulfamethoxazole

Indexed keywords

CEFTAZIDIME; COTRIMOXAZOLE; ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; APACHE; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; STENOTROPHOMONAS MALTOPHILIA; COMPARATIVE STUDY; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITAL MORTALITY; IMMUNOLOGY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; SHOCK, SEPTIC; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; APACHE; BACTEREMIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES; SHOCK, SEPTIC; STENOTROPHOMONAS MALTOPHILIA; TREATMENT OUTCOME; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION;

EID: 84904777535     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2014.06.005     Document Type: Article

References (45)

1. 1 Looney, W.J., Narita, M., Mühlemann, K., Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis 9 (2009), 312–323.
2. 2 Nicodemo, A.C., Paez, J.I., Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 26 (2007), 229–237.
3. 3 Abbott, I.J., Slavin, M.A., Turnidge, J.D., Thursky, K.A., Worth, L.J., Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment. Expert Rev Anti Infect Ther 9 (2011), 471–488.
4. 4 Muder, R.R., Optimizing therapy for Stenotrophomonas maltophilia. Semin Respir Crit Care Med 28 (2007), 672–677.
5. 5 Muder, R.R., Harris, A.P., Muller, S., Edmond, M., Chow, J.W., Papadakis, K., et al. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis 22 (1996), 508–512.
6. 6 Al-Jasser, A.M., Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem. Ann Clin Microbiol Antimicrob, 5, 2006, 23.
7. 7 Gales, A.C., Jones, R.N., Forward, K.R., Linares, J., Sader, H.S., Verhoef, J., Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997–1999). Clin Infect Dis 32 (2001), S104–S113.
8. 8 Toleman, M.A., Bennett, P.M., Bennett, D.M., Jones, R.N., Walsh, T.R., Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg Infect Dis 13 (2007), 559–565.
9. 9 Tan, C.K., Liaw, S.J., Yu, C.J., Teng, L.J., Hsueh, P.R., Extensively drug-resistant Stenotrophomonas maltophilia in a tertiary care hospital in Taiwan: microbiologic characteristics, clinical features, and outcomes. Diagn Microbiol Infect Dis 60 (2008), 205–210.
10. 10 Falagas, M.E., Valkimadi, P.E., Huang, Y.T., Matthaiou, D.K., Hsueh, P.R., Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother 62 (2008), 889–894.
11. 11 The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1. 2013. 2013, EUCAST, Basel, Switzerland.
12. 12 Araoka, H., Baba, M., Yoneyama, A., Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996–2009. Eur J Clin Microbiol Infect Dis 29 (2010), 605–608.
13. 13 Garazi, M., Singer, C., Tai, J., Ginocchio, C.C., Bloodstream infections caused by Stenotrophomonas maltophilia: a seven-year review. J Hosp Infect 81 (2012), 114–118.
14. 14 Friedman, N.D., Korman, T.M., Fairley, C.K., Franklin, J.C., Spelman, D.W., Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect 45 (2002), 47–53.
15. 15 Senol, E., DesJardin, J., Stark, P.C., Barefoot, L., Snydman, D.R., Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis 34 (2002), 1653–1656.
16. 16 Friedman, N.D., Kaye, K.S., Stout, J.E., McGarry, S.A., Trivette, S.L., Briggs, J.P., et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 137 (2002), 791–797.
17. 17 Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987), 373–383.
18. 18 Garner, J.S., Jarvis, W.R., Emori, T.G., Horan, T.C., Hughes, J.M., CDC definitions for nosocomial infections, 1988. Am J Infect Control 16 (1988), 128–140.
19. 19 Clinical and Laboratory Standards Institute (CLSI), Performance standards for antimicrobial susceptibility testing: 14th Informational Supplement. Document No. M100-S14, 2004, CLSI, Wayne, PA.
20. 20 Krueger, T.S., Clark, E.A., Nix, D.E., In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. Diagn Microbiol Infect Dis 41 (2001), 71–78.
21. 21 Carroll, K.C., Cohen, S., Nelson, R., Campbell, D.M., Claridge, J.D., Garrison, M.W., et al. Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 32 (1998), 229–235.
22. 22 Nseir, S., Di Pompeo, C., Brisson, H., Dewavrin, F., Tissier, S., Diarra, M., et al. Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome. Crit Care, 10, 2006, R143.
23. 23 Nyc, O., Matejková, J., Stenotrophomonas maltophilia: significant contemporary hospital pathogen - review. Folia Microbiol (Praha) 55 (2010), 286–294.
24. 24 Chang, Y.T., Lin, C.Y., Lu, P.L., Lai, C.C., Chen, T.C., Chen, C.Y., et al. Stenotrophomonas maltophilia bloodstream infection: comparison between community-onset and hospital-acquired infections. J Microbiol Immunol Infect 47 (2014), 28–35.
25. 25 Wang, W.S., Liu, C.P., Lee, C.M., Huang, F.Y., Stenotrophomonas maltophilia bacteremia in adults: four years' experience in a medical center in northern Taiwan. J Microbiol Immunol Infect 37 (2004), 359–365.
26. 26 Lai, C.H., Chi, C.Y., Chen, H.P., Chen, T.L., Lai, C.J., Fung, C.P., et al. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect 37 (2004), 350–358.
27. 27 Chien, J.Y., Hsueh, P.R., Yu, C.J., Yang, P.C., The evolution of drug-resistant microorganisms in patients with prolonged mechanical ventilation. Am J Infect Control 37 (2009), 231–236.
28. 28 Beceiro, A., Tomás, M., Bou, G., Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?. Clin Microbiol Rev 26 (2013), 185–230.
29. 29 Fernández, A., Pérez, A., Ayala, J.A., Mallo, S., Rumbo-Feal, S., Tomás, M., et al. Expression of OXA-type and SFO-1 beta-lactamases induces changes in peptidoglycan composition and affects bacterial fitness. Antimicrob Agents Chemother 56 (2012), 1877–1884.
30. 30 Foucault, M.L., Courvalin, P., Grillot-Courvalin, C., Fitness cost of VanA-type vancomycin resistance in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 53 (2009), 2354–2359.
31. 31 Paez, J.I., Costa, S.F., Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J Hosp Infect 70 (2008), 101–108.
32. 32 Ansari, S.R., Hanna, H., Hachem, R., Jiang, Y., Rolston, K., Raad, I., Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer. Cancer 109 (2007), 2615–2622.
33. 33 Tsiodras, S., Pittet, D., Carmeli, Y., Eliopoulos, G., Boucher, H., Harbarth, S., Clinical implications of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand J Infect Dis 32 (2000), 651–656.
34. 34 Giske, C.G., Monnet, D.L., Cars, O., Carmeli, Y., ReAct-Action on Antibiotic Resistance, Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 52 (2008), 813–821.
35. 35 The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay. Infect Control Hosp Epidemiol 23 (2002), 106–108.
36. 36 Mauldin, P.D., Salgado, C.D., Hansen, I.S., Durup, D.T., Bosso, J.A., Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother 54 (2010), 109–115.
37. 37 Lye, D.C., Earnest, A., Ling, M.L., Lee, T.E., Yong, H.C., Fisher, D.A., et al. The impact of multidrug resistance in healthcare-associated and nosocomial Gram-negative bacteraemia on mortality and length of stay: cohort study. Clin Microbiol Infect 18 (2012), 502–508.
38. 38 Cheong, H.S., Lee, J.A., Kang, C.I., Chung, D.R., Peck, K.R., Kim, E.S., et al. Risk factors for mortality and clinical implications of catheter-related infections in patients with bacteraemia caused by Stenotrophomonas maltophilia. Int J Antimicrob Agents 32 (2008), 538–540.
39. 39 Boktour, M., Hanna, H., Ansari, S., Bahna, B., Hachem, R., Tarrand, J., et al. Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients. Cancer 106 (2006), 1967–1973.
40. 40 Wu, H., Wang, J.T., Shiau, Y.R., Wang, H.Y., Lauderdale, T.L., Chang, S.C., A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan. J Microbiol Immunol Infect 45 (2012), 120–126.
41. 41 Zelenitsky, S.A., Iacovides, H., Ariano, R.E., Harding, G.K., Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 51 (2005), 39–43.
42. 42 Liaw, S.J., Teng, L.J., Hsueh, P.R., Ho, S.W., Luh, K.T., In vitro activities of antimicrobial combinations against clinical isolates of Stenotrophomonas maltophilia. J Formos Med Assoc 101 (2002), 495–501.
43. 43 Tatman-Otkun, M., Gürcan, S., Ozer, B., Aydoslu, B., Bukavaz, S., The antimicrobial susceptibility of Stenotrophomonas maltophilia isolates using three different methods and their genetic relatedness. BMC Microbiol, 5, 2005, 24.
44. 44 Masgala, A., Galani, I., Souli, M., Giamarellou, H., Discrepancies between various methods in susceptibility testing and epidemiological analysis of Stenotrophomonas maltophilia clinical isolates. Cent Eur J Public Health 18 (2010), 119–123.
45. 45 Clinical and Laboratory Standards Institute (CLSI), Performance standards for antimicrobial susceptibility testing: 24th Informational Supplement. Document No. M100-S24, 2014, CLSI, Wayne, PA.